食道疾病介入 胃疾病介入 胰腺疾病介入 胆道系统疾病的介入治疗 肝脏疾病介入 小肠疾病介入 结肠疾病介入 非食道静脉曲张消化道出血的介入治疗 骶前囊肿经皮穿刺引流 经皮胃肠造瘘 经皮空肠造瘘
返回首页
当前位置: 首页 > 介入医学各论 > 消化介入 >
  • [重复导管 vs 动脉港] HAIC研究潜在障碍:重复导管术 vs 药盒置入 日期:2021-12-28 13:34:36 点击:99

    Two different percutaneous arterial access approaches have been used for HAIC: the first approach entails the use of implantable port-catheter systems, and the second approach involves repeated hepatic artery catheterization. 两种不同的经...

  • [多种化疗方案] HAIC研究的潜在障碍:多种化疗方案 日期:2021-12-28 11:54:22 点击:99

    A standard chemotherapy regimen for HAIC has yet to be established, increasing the challenge of interpreting trial results. HAIC的标准化疗方案尚未建立,这增加了解释试验结果的挑战。 Cisplatin and 5-FU were the most commonly used chemotherap...

  • [异质性患者数据] HAIC研究潜在障碍:数据的异质性 日期:2021-12-27 15:27:25 点击:99

    Studies on HAIC have included populations with various degrees of intrahepatic tumor burden, including the possible presence of PVT/EHS. 对HAIC的研究包括了不同程度肝内肿瘤负荷的人群,包括可能存在PVT/EHS。 Studies on patients with PVT who r...

  • [+ 免疫治疗] HAIC 联合免疫治疗 日期:2021-12-27 08:50:24 点击:99

    Immune checkpoint inhibitorbased combinations have changed the treatment paradigm for advanced HCC [59,60] and are likely to remain the cornerstone of systemic treatment in the next few years. 基于免疫检查点抑制剂的联合治疗已经改变了晚期HC...

  • [+ 放疗] HAIC 联合放疗 日期:2021-12-25 11:25:23 点击:99

    HAIC combined with radiation therapy (RT) has also been extensively investigated, particularly in subgroups of patients with PVT. HAIC联合放疗(RT)也已被广泛研究,特别是在PVT患者的亚组中。 Han et al. [ 51 ] conducted a small-scale single-ar...

  • [+ 多激酶抑制剂] HAIC联合多激酶抑制剂 日期:2021-12-25 07:06:16 点击:99

    HAIC has been combined with sorafenib to leverage the synergistic effects of the combination. HAIC已与索拉非尼联合使用,以利用该联合使用的协同效应。 A randomized Phase 2 trial was conducted to compare HAIC plus sorafenib with sorafenib alo...

  • [+ 干扰素α] HAIC联合皮下干扰素α 日期:2021-12-24 23:56:05 点击:99

    Subcutaneous or intramuscular interferon-alpha (IFN-) has been used in combination with intravenous chemotherapy for advanced HCC to enhance antitumor activity [55]. 皮下或肌内干扰素(IFN-)已与静脉化疗联合用于晚期HCC,以增强抗肿瘤活性[ 55 ]...

  • [定义] 非肝硬化门静脉高压定义 日期:2021-12-13 13:32:09 点击:99

    肝( 窦) 前型非肝硬化门静脉高压症( non - cirrhotic portal hypertension,NCPH) 是一组预后可能较好、病因少见或复杂的门静脉系统或全身性疾病,肝脏功能基本正常、肝 静 脉 压 力 梯 度 ( hepatic venous pressure gradient,HVPG) 正常或轻度增加为特征...

  • [难治性肝性胸腹水] TIPS适应症:肝性胸水 日期:2021-12-13 12:14:59 点击:99

    肝性胸水(Hepatic hydrothorax,HH) HH is the accumulation of a significant amount of transudative fluid, usually over 500 mL, in the pleural cavity of patients with decompensated liver cirrhosis without coexisting primary cardiopulmonary...

  • [难治性腹水] TIPS适应症:腹水 日期:2021-12-10 17:14:38 点击:99

    Ascites is the most common complication of PH in cirrhosis, with approximately 60% of compensated cirrhosis patients developing the condition within ten years of diagnosis[74]. 腹水是肝硬化中PH最常见的并发症,约60%的代偿性肝硬化患者在诊断...

  • 首页
  • 上一页
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 下一页
  • 末页
  • 81808
推荐内容